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Abstract
Allergic reactions towards b-lactam antibiotics pose an important clinical problem. The ability of small molecules, such as a
b-lactams, to bind covalently to proteins, in a process known as haptenation, is considered necessary for induction of a
specific immunological response. Identification of the proteins modified by b-lactams and elucidation of the relevance of
this process in allergic reactions requires sensitive tools. Here we describe the preparation and characterization of a
biotinylated amoxicillin analog (AX-B) as a tool for the study of protein haptenation by amoxicillin (AX). AX-B, obtained by
the inclusion of a biotin moiety at the lateral chain of AX, showed a chemical reactivity identical to AX. Covalent
modification of proteins by AX-B was reduced by excess AX and vice versa, suggesting competition for binding to the same
targets. From an immunological point of view, AX and AX-B behaved similarly in RAST inhibition studies with sera of
patients with non-selective allergy towards b-lactams, whereas, as expected, competition by AX-B was poorer with sera of
AX-selective patients, which recognize AX lateral chain. Use of AX-B followed by biotin detection allowed the observation of
human serum albumin (HSA) modification by concentrations 100-fold lower that when using AX followed by immunological
detection. Incubation of human serum with AX-B led to the haptenation of all of the previously identified major AX targets.
In addition, some new targets could be detected. Interestingly, AX-B allowed the detection of intracellular protein adducts,
which showed a cell type-specific pattern. This opens the possibility of following the formation and fate of AX-B adducts in
cells. Thus, AX-B may constitute a valuable tool for the identification of AX targets with high sensitivity as well as for the
elucidation of the mechanisms involved in allergy towards b-lactams.
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Introduction
Protein modification by reactive drugs or their metabolites is an
important process in adverse drug reactions. In allergic drug
reactions in particular, covalent protein modification by drugs is
thought to be necessary to give rise to a structure of sufficient size
to trigger an immune response. In this process, the drugs, or
haptens, covalently modify proteins (haptenation). Haptenated
proteins will be processed by antigen presenting cells and the
resulting peptides exposed through MHCI or MHCII-dependent
pathways. Alternative mechanisms imply the covalent or non-
covalent binding of the drug to the peptides already exposed on
the cell surface or to MHC or T-cell receptors [1,2] (reviewed in
[3]). Drug covalent or non-covalent adducts will be engaged by
receptors on lymphocytes to elicit a CD4+ or CD8+ cell response
or a T-cell response.
b-Lactam antibiotics are the drugs most frequently eliciting
allergic reactions. Among the various b-lactams, the trend of
allergic reactions has been changing during recent years in
correlation with the patterns of prescription and frequency of
consumption [4]. Therefore, at present, amoxicillin (AX) is the
antibiotic most frequently eliciting allergic reactions [5]. In
addition, reactions towards clavulanic acid (CLV) are on the rise
[6].
A drawback of diagnostic tests for drug allergy is the fact that
the isolated drug or synthetic drug-protein conjugates are often not
recognized by patients’ drug specific IgE. In addition, antibodies
generated against b-lactam conjugates or present in the serum of
allergic patients do not recognize equally well the drug when
conjugated to different carrier structures [7–10]. Similarly,
activation of T-cell clones may occur selectively in response to
free drug or to drug conjugates [1]. Therefore, accumulating
experimental and clinical evidence raises the hypothesis that not
only the drug, but parts of the haptenated protein or peptide may
contribute important structural determinants for antigen recogni-
tion [11]. In this context, identification of haptenated proteins may
provide valuable information to understand the mechanisms of
allergy as well as to improve the diagnostic procedures.
From a chemical point of view, the reactivity of b-lactam
antibiotics depends on the b-lactam ring, which may suffer the
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attack of various nucleophiles present in proteins, mainly, the
amino-terminal groups, the amino groups of the lateral chains of
lysine residues, the imidazole ring of histidine residues or the thiol
group of cysteine residues [12]. The electrophilic character of the
b-lactam ring is related to the strained four member ring next to
the thiazolidine ring. The nucleophilic attack results in the opened
form of the b-lactam structure, which is stable in the case of
penicillins.
From a pathophysiological point of view it has been shown that
there is selectivity in the allergic responses and in the recognition
of b-lactams by the sera of patients allergic to these antibiotics.
Thus, some patients develop allergic reactions selective towards
AX but not towards other b-lactams, whereas others suffer allergic
reactions towards several b-lactams [5,11]. Similarly, in diagnostic
tests, for some patients binding of IgE present in sera to an
immobilized antibiotic can be competed by several b-lactams with
similar potency (non-selective allergic patients), whereas for other
patients, AX is a more effective competitor (AX-selective allergic
patients) [13,14]. Since the structural feature specific of AX is the
lateral chain of the molecule, these observations are interpreted as
the antibodies being directed towards this part of the molecule in
the ‘‘selective’’ patients and towards the core structure of the
molecule in the ‘‘non-selective’’ patients. At present it is not known
whether formation of different haptenated structures contributes
to this selectivity.
Protein haptenation by b-lactams has been addressed in various
studies. Early works on the detection and identification of b-
lactam-protein adducts involved HPLC purification, followed by
EDMAN degradation [15]. This allowed the identification of
several addition sites for penicillin in human serum albumin
(HSA), all of which mapped at lysine residues. More recently, both
MS and immunological approaches have been used by several
groups. Immunological procedures allowed the identification of
some serum proteins, including HSA and transferrin, as targets for
haptenation by ampicillin [16]. Similarly, an anti-flucloxacillin
antibody has been used to detect adducts formed in the liver of
flucloxacillin-treated rats [17]. From the various studies available it
is inferred that the main target for protein haptenation is HSA.
The specificity and sensitivity of the current MS approaches has
led to the detailed characterization of the modification of HSA by
various b-lactams, both in vitro and in samples obtained from
patients [12,18].
Recently, we have used a combination of immunological and
high resolution MS approaches to identify several targets for
haptenation by AX [12]. Identified targets include HSA,
transferrin and heavy and light chains of immunoglobulins.
Moreover, we have evidenced that factors independent from
protein abundance influence modification by AX. In addition,
both, residue reactivity and conformational factors are important
for this process. These factors result in the preferential modifica-
tion of some serum proteins and, in the case of HSA, in the
preferential modification of certain residues, particularly Lys190
[12].
Given the importance of the interplay between AX-protein
adducts and immune cells for the allergic reaction, we sought to
develop approaches to monitor these processes with high
sensitivity tools. The avidin-biotin interaction provides great
affinity and sensitivity, and the possibility of coupling modification
of proteins by biotinylated compounds with several methods for
detection, purification and imaging [19,20]. Here we obtained an
AX-B derivative via an amide linkage between the amino group of
the lateral chain of AX and biotin-NHS ester. In addition, we have
explored the potential of AX-B to form adducts with proteins and
its suitability as a tool for the study of the mechanisms involved in
AX allergy. We show that AX-B is able to form adducts with
proteins giving a pattern similar to that given by AX. Moreover, it
allows the detection of adducts with 10 to 100-fold higher
sensitivity than formerly used immunological methods, allowing
the detection of both extra- and intracellular adducts. These
findings open new ways for the study of protein haptenation by
AX and its importance in the development of allergic reactions.
Materials and Methods
Ethics statement
The study was conducted according to the Declaration of
Helsinki principles and was approved by the Ethics Committee of
Carlos Haya Hospital (Ma´laga, Spain). All subjects included in the
study were informed orally about the study and signed the
corresponding informed consent.
Reagents
Amoxicillin was from Glaxo Smithkline Beecham (Madrid,
Spain). Deuterium oxide for NMR studies (D2O) was from
Panreac Quı´mica SAU (Barcelona, Spain). Potassium phosphate
buffer (PBS) for 1H-NMR reactivity studies was prepared in 99.8%
D2O at pH 7.4. HRP-Streptavidin and ECL system were from
GE Healthcare. Alexa-488 streptavidin was from Molecular
Probes. Albumin from human serum, phorbol myristate acetate,
iodoacetamide and 49,6-diamidino-2-phenylindole dihydrochlo-
ride (DAPI) were from Sigma. Biotin-NHS ester was from Aldrich.
Preparation of AX-B
Amoxicillin (77 mg, 0.2 mmol) and Biotin-NHS ester (68 mg,
0.2 mmol) were placed in a 10 ml round bottom flask. The flask
was degassed. Once the argon atmosphere was achieved, the flask
was introduced in an ice-water bath (0uC) and 3 ml of methanol
was added. The mixture was stirred for 5 minutes and then 35 ml
(0.2 mmol) of triethylamine was added. The reaction was stirred
for 2 hours in the ice-water bath, ensuring that the temperature
was kept at 0uC, and 1 hour at room temperature (25–27uC).
The reaction mixture was lyophilized and a white solid
obtained, corresponding to the AX-B triethyl ammonium salt.
Yield 80%. White solid. 1H-NMR (400 MHz, D2O) d ppm:
7.36 (d, 2H, J= 8.7 Hz, Ar), 6.97 (d, 2H, J= 8.7 Hz, Ar), 5.55–
5.48 (m, 2H, H5, H6), 5.46 (s, 1H, H10), 4.66–4.61 (m, 1H, H20),
Figure 1. Synthetic procedure for AX-B.
doi:10.1371/journal.pone.0090891.g001
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Figure 2. 1H-NMR spectra of (A) AX-B and (B) AX recorded in D2O.
doi:10.1371/journal.pone.0090891.g002
Figure 3. Reactivity of AX and AX-B. 1H NMR of each amoxicillin: (A) AX-B and (B) AX, in presence of butylamine in D2O after 15 min. Arrows
point at signals corresponding to H5 and H6, used to monitor the reaction.
doi:10.1371/journal.pone.0090891.g003
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4.40–4.37 (m, 1H, H24), 4.23 (s, 1H, H3), 3.33–3.28 (m, 1H, H17),
3.25 (q, 6H, J= 7.3 Hz 2CH2CH3), 3.07–3.00 (m, 2H, H19),
2.84–2.80 (m, 2H, H16), 2.39 (t, 2H, J= 7.1 Hz, H13), 1.79–1.66
(m, 4H, H14, H15), 1.53 (s, 3H, 2CH3), 1.49 (s, 3H, 2CH3), 1.33
(t, 9H, J= 7.3 Hz, 2CH2CH3). EI-MS m/z (%): 86 (100), 100 (48),
107 (27), 166 (44), 183 (23), 185 (7), 227 (5), 335 (1).
Evaluation of AX-B reactivity
A solution of AX or AX-B with butylamine in deuterated
solvent was added to appropriate NMR tubes, as described the
following: each amoxicillin (15?1026 mol) was dissolved in 0.5 ml
of deuterated solvent (D2O or deuterated PBS), and an excess of
butylamine (5?1026 l, 50?1026 mols) was added. The reactions
were monitored by 1H NMR on a Bruker ASCENDTM
400 MHz.
In vitro formation and detection of AX-HSA and AX-B-
HSA adducts
HSA was dissolved at 10 mg/ml in PBS pH 7.4 or 50 mM
Na2CO3/NaHCO3 pH 10.2, as indicated, and incubated with
various concentrations of AX or AX-B at 37uC for 16 h. Before
analysis, the incubation mixture was diluted in PBS and aliquots
containing 2 mg of protein were loaded onto 10% polyacrylamide
gels. After SDS-PAGE, gels were transferred to Immobilon P
membranes using a semi-dry transfer system from Bio-Rad. For
immunological detection, blots were incubated with AO3.2 anti-
AX adducts monoclonal antibody [21] at 1:1000 dilution, followed
by secondary antibody HRP-conjugated anti-mouse immunoglob-
ulins (Igs) at 1:2000 dilution, and proteins of interest were detected
with ECL. For detection of AX-B-HSA adducts, blots were
incubated with HRP-streptavidin (1:1000 dilution), and biotin-
positive signals were detected with ECL.
In vitro modification and analysis of serum proteins
modified by AX or AX-B
Human serum obtained from healthy donors (Sigma) was
incubated at 30 mg of protein/ml in the absence or presence of
AX or AX-B, as indicated, in PBS at 37uC for 16 h. For SDS-
PAGE analysis, serum samples were diluted with PBS and aliquots
containing 2 mg of protein were loaded onto 12.5% polyacryl-
amide gels. For 2D analysis, 70 mg of protein were precipitated
with chloroform:methanol, using the method of Wessel and Flugge
[22]. The precipitated proteins were resuspended in 140 ml of IEF
sample buffer (4% CHAPS, 2 M thiourea, 7 M urea, 100 mM
DTT, and 0.4% Bio-lyte ampholytes) and loaded on ReadyStrip
IPG Strips (pH 3–10, Bio-Rad) for isoelectric focusing on a
Protean IEF cell (Bio-Rad), following the instructions of the
manufacturer. Before the second dimension, strips were equili-
brated in 6 M urea, 2% SDS, 0.375 M Tris, pH 8.8, 20% (vol/
vol) glycerol, containing 130 mM DTT for the first equilibration
step and 135 mM iodoacetamide for the second step. Strips were
then placed on top of 12.5% polyacrylamide SDS gels. Detection
of modified proteins was performed as above.
Cell culture and treatments
RAW264.7 murine macrophage cells from the American Tissue
Culture Collection (ATCC, Manassas, VA) were cultured in
DMEM plus 10% (vol/vol) fetal bovine serum (FBS), 100 U/ml
penicillin and 100 mg/ml streptomycin in a humidified atmo-
sphere, as previously described [23]. THP-1 human acute
monocytic leukemia cells (ATCC) and RPMI 8866 human B-
lymphocyte cells [24] were cultured in RPMI 1640 supplemented
with serum and antibiotics. When indicated, cells were cultured in
antibiotic-free medium 48 h before treatment with AX or AX-B.
After treatments, cells were washed with PBS and lysed in 50 mM
Tris-HCl, pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.1 mM 2-
mercaptoethanol, 1% NP-40 or 0.5% SDS, containing 0.1 mM
sodium orthovanadate, 50 mM sodium fluoride and protease
inhibitors (2 mg/ml each of leupeptin, aprotinin and trypsin
inhibitor, and 0.32 mg/ml AEBSF).
Confocal microscopy
RAW264.7 cells grown on glass coverslips were cultured in the
absence or presence of AX-B at 0.5 mg/ml for 24 h. For
visualization of biotin-positive structures cells were fixed with
4% paraformaldehyde for 30 min and stained with Alexa488-
streptavidin, as previously described [19]. Nuclei were counter-
stained with DAPI. Fluorescence images shown are single z
sections obtained with a Leica DMRE2 confocal microscope.
Patients
The study of the reactivity of sera from allergic patients towards
AX-B included patients who had been diagnosed with an
immediate allergic reaction to AX using the diagnostic procedure
described in the ENDA protocol [25]. Patients were classified into
two groups: Group A (patients with allergic reactions selective to
AX), those with a skin test or drug provocation test (DPT) positive
to AX and confirmed good tolerance to benzylpenicillin (BP) by
DPT; Group B (patients with allergic reactions cross-reactive to BP
and AX), those with positive skin test to BP determinants or
positive DPT to BP. Subjects with negative skin test to both BP
and AX determinants and with good tolerance to AX were used as
controls.
Figure 4. Modification of HSA by AX and AX-B. (A) HSA was
incubated in the presence of the indicated concentrations of Ax or Ax-B
and adduct formation was assessed by western blot and detection with
an anti-AX antibody (AO3.2) or with HRP-streptavidin. Exposure times
were 5 minutes for AX and one second for AX-B detection, respectively.
(B) HSA was incubated with AX or AX-B at 0.5 mg/ml for 16 h at 37uC.
Aliquots of the incubation mixture containing the indicated amounts of
total protein were analyzed by SDS-PAGE and adducts formed were
detected as above. Exposure times were 2 minutes for AX and one
second for AX-B detection, respectively.
doi:10.1371/journal.pone.0090891.g004
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Skin testing
Skin testing was carried out as described [25], using 0.03 ml of
solution prepared daily. The reagents used were penicilloyl
polylysine (PPL) (Diater, Madrid, Spain) at 561025 and
561024 mM, minor determinant mixture (MDM) (Diater, Ma-
drid, Spain) at 261022 and 2610 mM, and AX (Glaxo Smithk-
line, Madrid, Spain) at 2 and 20 mg/ml.
In the skin prick tests, a wheal larger than 3 mm with a negative
response to the control saline was considered positive. In the
intradermal tests, the wheal area was marked initially and 20 min
after testing, and an increase in diameter greater than 3 mm was
considered positive [26].
Drug provocation test
Drug provocation test (DPT) was carried out in all patients in a
single-blind procedure following the previously described protocol
[25,27] in accordance with the ENDA recommendations. DPT
consists in the administration of increasing doses of BP (Normon
Laboratories, Madrid, Spain) and/or AX (Glaxo Smithkline,
Madrid, Spain) at regular intervals of time (30–60 minutes) to
achieve the therapeutic dose. The test was considered positive
when symptoms compatible with an immediate response appeared
with any of the incremental concentrations used.
Specific IgE antibodies determination
Levels of serum specific IgE from patients were quantified by
using radioallergoabsorbent test (RAST) as previously described
[28]. BP (Normon Laboratories, Madrid, Spain) and AX (Glaxo
Smithkline, Madrid, Spain) at 20 mg/ml were conjugated to poly-
L-lysine (PLL) (Sigma, St Louis, MO, USA) at 10 mg/ml
previously bound to cyanogen bromide-activated cellulose discs
(nu 54, Whatman International Ltd, Maidstone, Kent, United
Kingdom) as described [7,29] and control discs with PLL and no
conjugated drugs were also obtained. RAST was performed
following the protocol described by Wide et al. [30] by incubating
sera from patients with the solid phase for 3 hours. Radiolabelled
anti-IgE antibody with I125 (kindly provided by ALK-Abello,
Madrid, Spain) was then added and samples were incubated
overnight. The radioactivity was then measured in a gamma
counter (Packard BioScience Company, Frankfurt, Germany) as
counts per minute (cpm). Results were calculated as a percentage
of the maximum of cpm (% RAST) and considered positive if they
were higher than 2.5% of label uptake, which was the mean 62
SD of the negative control group.
%RAST~
cpmBPO=AXO{PLL{cpmPLL
cpmmax imum
x100
Determination of IgE specificity and cross-reactivity: RAST
inhibition
RAST inhibition was performed as previously reported
[7,28,31]. Sera from patients with RAST values higher than 7%
to both benzyl penicilloyl-PLL (BPO-PLL) and amoxicilloyl acid-
PLL (AXO-PLL) or only to AXO-PLL were incubated with AX or
AX-biotin at 10-fold serial dilutions (100, 10 and 1 mM, final
concentrations) in PBS for 3 hours. Then, solid phase conjugated
with AXO-PLL were added and the RAST procedure continued
as described above. Results were expressed as percentage of
inhibition calculated according to the following formula:
%Inhibition~
(%RASTnon{inhibited{%RASTinhibited )
%RASTnon{inhibited
x100
Results
Synthesis and characterization of AX-B
The derivatization of AX with biotin NHS-ester was carried out
as described in the Experimental Section. The reaction was
optimized until there were no evidences of b-lactam ring opening.
A schematic view of the reaction and the resulting compound (AX-
B) is shown in Fig. 1. 1H-NMR analysis of AX-B confirms the
chemical structure of the AX-B derivative (Fig. 2).
AX and AX-B display similar reactivity towards
butylamine
We compared the acylation abilities of AX and AX-B towards a
simple nitrogen nucleophile by reaction of either b-lactam with
butylamine at NMR scale. Butylamine mimics the lateral chain of
lysine, and conjugates of butylamine to various penicillins have
been previously used for epitope mapping of b-lactam antibiotics
[21]. The characteristic 1H chemical shifts for protons H-5 and H-
6 in the b-lactam ring of AX were used to monitor the reaction.
First, we quickly tested the reactivity using D2O as solvent, and
Figure 5. Competition between AX and AX-B for modification
of HSA. (A) HSA was incubated overnight with a 9-fold molar excess of
AX or AX-B in bicarbonate buffer and detection of adducts was
achieved by western blot with an anti-AX antibody (AO3.2) or with HRP-
streptavidin, as indicated. (B) HSA was incubated in the absence or
presence of AX-B, as above, followed by an overnight incubation with
AX. Binding of AX was assessed by western blot with AO3.2 antibody.
(C) HSA was incubated for 2 h with 80 mM AX-B, after a 16 h pre-
incubation with the indicated concentrations of AX, expressed in molar
excess with respect to AX-B. Aliquots of the incubation containing 2 mg
of protein were subjected to SDS-PAGE and transfer, and incorporation
of AX-B was assessed by detection with HRP-streptavidin. Blots shown
in every case are representative of three independent assays with
similar results.
doi:10.1371/journal.pone.0090891.g005
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after 15 minutes, both b-lactams yielded 95% of amide linkage
with butylamine (Fig. 3). In addition, these reactions were carried
out in similar conditions to our protein experimental studies
(pH 7.4, 37uC and 16 h of incubation time), and only the products
corresponding to the aminolysis of the b-lactams were detected
(data not shown).
Modification of HSA by AX and AX-B
HSA is one of the major targets for haptenation by AX in
human serum. As we previously described [12], the modification
of HSA by AX could be detected by Western blot using the anti-
AX monoclonal antibody AO3.2 (Fig. 4). Under the conditions of
our assay, this procedure allowed the detection of HSA modified
in the presence of 0.5 mg/ml AX at neutral pH (Fig. 4A).
Remarkably, in the case of AX-B, the HSA adduct could be
detected after incubation of the protein with concentrations of the
antibiotic as low as 5 mg/ml. The superior sensitivity of Ax-B was
also evidenced by a dilution approach (Fig. 4B). HSA was modified
by incubation of AX or AX-B at 0.5 mg/ml and decreasing
amounts of the incubation mixtures were analyzed by SDS-PAGE
and blot followed by immunological or HRP-streptavidin detec-
tion. Using this approach, detection of AX-modified HSA
required at least 0.2 mg of protein and long exposure times,
whereas modification by AX-B could be clearly detected with
Figure 6. Recognition of AX and AX-B by the sera of allergic patients. Shown are RAST inhibition assays using in the solid phase AXO-PLL
discs and in the fluid phase AX and AX-biotin, at the indicated concentrations. Results are from selective allergic patients to AX (A, patients 1–4) and
from cross-reactive allergic patients (B, patients 5–8).
doi:10.1371/journal.pone.0090891.g006
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0.02 mg after 1 s exposure, whereas after 1 min, modification
could be detected even with 0.002 mg of protein (not shown).
The monoclonal antibody AO3.2 recognizes the lateral chain of
AX [21]. Consistent with this specificity, this antibody did not
recognize HSA modified by AX-B, since in this compound the
lateral chain is altered by the introduction of the biotin moiety
(Fig. 5A). Therefore, we took advantage of this specificity to
explore whether there was a competition between both antibiotics
for binding to HSA. Incubation of HSA in the presence of an
excess of AX-B precluded the incorporation of AX, as detected
with the AO3.2 antibody (Fig. 5B). Conversely, pre-incubation of
HSA with an excess of AX reduced the incorporation of AX-B, as
evidenced by incubation with HRP-streptavidin and ECL
detection (Fig. 5C).
Recognition of AX-B by the serum of patients allergic to
AX
Next, we wanted to assess the ability of sera from allergic
patients to recognize AX-B. Thus, the validation study included 8
patients (5 men and 3 women) with immediate allergic reactions to
AX (Table 1). 4 subjects were included in group A (showing
selectivity towards AX) and 4 subjects in group B (showing cross-
reactivity with BP).
RAST inhibition studies were performed in 8 cases with a high
RAST binding value (.7%), 4 patients from group A (1A, 2A, 3A
and 4A) and 4 patients from group B (5B, 6B, 6B and 8B). We
observed a better recognition of AX than AX-B in assays using
serum from patients with IgE specific for AX (group A, AX-
selective patients), which recognizes mainly the lateral chain
Table 1. Clinical characteristics and skin test and drug provocation test results of the patients included in the study.
Patient Group Age (y)Sex
Time interval
reaction-study
(months) Reaction Drug
Time interval
drug-reaction
(min) Skin test DPT
PPL MDM AX BP AX
1 A 43 M 8 anaphylaxis AX-CLV 80 2 2 + 2 nd
2 A 54 F 8 Anaphylactic shock AX Less than 60 2 2 + 2 nd
3 A 43 M 4 anaphylaxis AX-CLV Less than 60 2 2 + 2 nd
4 A 55 M 2 Urticaria angioedema AX-CLV 10 2 2 + 2 nd
5 B 18 F 6 anaphylaxis BP 5 + 2 + nd nd
6 B 36 M 0.6 Anaphylactic shock AX 10 + 2 + nd nd
7 B 61 F 2 Urticaria AX-CLV 120 + + + nd nd
8 B 51 M 6 anaphylaxis AX 120 + 2 + nd nd
y: years; PPL: penicilloyl-polylysine; MDM: minor determinant mixture; AX: amoxicillin; CLV: clavulanic acid; DPT: drug provocation test; BP: benzylpenicilloyl; nd, not
done.
doi:10.1371/journal.pone.0090891.t001
Table 2. RAST and RAST inhibition results from patients with RAST values higher than 7% to AXO-PLL and/or BPO-PLL.
Patient % RAST Inhibitor % RAST inhibition
BPO-PLL AXO-PLL 100 mM 10 mM 1 mM
1 0.00 25.58 AX 88.5 81.3 79.1
AX-biotin 85.6 74.1 32.4
2 0.20 33.11 AX 79.6 52.9 12.4
AX-biotin 61.3 22.6 9.0
3 1.68 29.68 AX 82.6 73.1 66.7
AX-biotin 69.5 64.1 26.9
4 0.00 29.80 AX 79.2 62 28.5
AX-biotin 48.6 14.4 0.0
5 51.17 26.30 AX 74.0 74.0 42.7
AX-biotin 86.0 68.0 27.3
6 25.53 28.92 AX 74.0 51.7 15.9
AX-biotin 70.2 44.1 11.7
7 39.96 42.82 AX 6.6 7.1 0.0
AX-biotin 0.0 0.0 0.0
8 28.61 33.28 AX 74.1 66.7 59.3
AX-biotin 69.8 58.0 38.9
doi:10.1371/journal.pone.0090891.t002
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structure of AX (Figure 6A, Table 2). Nevertheless, specific serum
IgE antibodies from cross-reactive patients (group B), which
recognize the structure of the molecule common to other
penicillins, namely, the 6-aminopenicillanic acid, recognized both
AX and AX-B with similar affinities (Figure 6B, Table 2). Results
obtained in these assays suggested that the conjugation of biotin to
the side chain amino group of AX interferes with the recognition
of this structure in the case of selective allergic reactions. No
significant inhibition was obtained in the assays made with control
sera, which suggested that biotin conjugated to AX is not non-
specifically recognized by total serum IgE antibodies (data not
shown).
Modification of serum proteins by AX and AX-B
As previously described by us and shown in Fig. 7A and C,
besides HSA, other serum proteins may be targets for AX
modification [12]. Therefore, we next explored the ability of AX-B
to form adducts with serum proteins. As shown in Fig. 7B,
incubation of human serum with AX-B led to the formation of
adducts with various proteins, which could be detected by HRP-
streptavidin after 2D-electrophoresis. Most of biotin-positive spots
coincided with those modified by AX and detected by western blot
with AO3.2, and corresponded to those previously identified as
HSA (spot 1), light and heavy chains of immunoglobulins (spots
3,4 and 5,6, respectively) and transferrin (spot 2) [12]. The position
of the targets in the Coomassie-stained membrane is shown in
Fig. 7C. Moreover, as observed with purified HSA, AX-B allowed
the detection of protein adducts with higher sensitivity, with at
least 10-times lower concentrations of AX-B being required to
elicit a detectable modification. This allowed the observation of a
biotin signal associated with haptoglobin 2 (spots 7 and 8), which
was negative with AO3.2. Apolipoprotein A1 (spot 9) was negative
with both procedures. For detailed MS data on the identification
of the various serum proteins please see [12]. Control samples gave
negligible background after either immunological or biotin
detection. Similar to above, incubation of human serum in the
presence of an excess AX reduced the incorporation of AX-B into
serum proteins (Fig. 7D).
Detection of intracellular protein adducts with AX-B
According to the hapten hypothesis, drugs could either bind to
extracellular proteins that would be endocytosed by cells, or bind
to intracellular components. In both cases, drug-protein conju-
gates would be proteolysed and peptides presented on the cell
surface [3]. Therefore, we attempted the detection of AX or AX-
B-adducts in cells (Fig. 8). Incubation of RAW264.7 murine
macrophages with high concentrations of AX followed by
immunological detection revealed only a weak increase in the
signal of certain bands over the background (Fig. 8A). Interest-
ingly, incubation with AX-B resulted in the incorporation of the
biotinylated antibiotic into several discrete bands, the most intense
of which showed apparent molecular weights of 70, 100 and
200 kDa (Fig. 8B). These bands were distinct from the major
endogenous biotinylated proteins, which appeared at 75 and
125 kDa and likely correspond to propionyl CoA and pyruvate
carboxylases, respectively [32]. The increase in the biotin signal
Figure 7. Modification of serum proteins by AX-B. Total human serum was incubated in the presence of the indicated concentrations of AX or
AX-B, for 16 h, after which, 70 mg of protein were analyzed by 2D electrophoresis, as described in the experimental section. (A) and (B) AX and AX-B-
modified proteins were visualized by detection with AO3.2 antibody or HRP-streptavidin, as indicated. Exposure times were 3 min and 5 seconds,
respectively. (C) Coomassie staining of one gel showing the positions of the identified proteins. 1, HSA; 2, transferrin; 3, 4 heavy chains of Igs; 5, 6,
light chains of Igs; 7, 8, haptoglobin 2; 9, apolipoprotein A1. (D) Total human serum was incubated with 0.1 mg/ml AX-B (0.16 mM) for 2 h after a
16 h pre-incubation with the indicated concentrations of AX, expressed in molar excess with respect to AX-B. Aliquots of the incubations containing
0.5 mg of protein were resolved on a 10% polyacrylamide gel, before transfer and detection with HRP-streptavidin. The positions of transferrin, HSA
and heavy and light chains of Igs, from top to bottom, are marked by asterisks.
doi:10.1371/journal.pone.0090891.g007
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associated to the putative AX-B targets was not due to the extra
supply of biotin since incubation of RAW264.7 cells with biotin
did not result in biotin labeling of proteins (Fig. 8C). Interestingly,
incubation of macrophages in the presence of an excess AX
reduced the formation of adducts containing AX-B (Fig. 8D). In
order to explore the localization of AX-B adducts we took
advantage of the possibility of detecting biotin by confocal
microscopy using fluorescent streptavidin (Fig. 9A). In these assays
cells were incubated with AX-B in the absence of serum to
minimize the potential contribution of serum proteins to the
signals observed. Control cells showed a nearly undetectable
perinuclear signal, typical of the mitochondrial localization of
various endogenous biotinylated proteins [19]. In contrast, cells
incubated in the presence of AX-B showed bright biotin-positive
intracellular structures distributed throughout the cytoplasm. A
blot of an experiment run in parallel, showing the main adducts
detected under these conditions, is depicted in Fig. 9B (left panel).
Next, we were interested in exploring whether the formation of
AX-B protein adducts displayed cell type-specific features. As
shown in Fig. 9B (middle and right panels), modified proteins in
extracts from AX-B-treated THP-1 monocytic and B-lymphoma
cells show different patterns, and differ also from those observed in
RAW264.7 macrophages. These results indicate that the nature or
the processing of the haptenated proteins may be cell type-
dependent. Although at present the mechanism(s) of entry of AX-
B or AX-B-protein conjugates into cells are not known, these
observations indicate the presence of intracellular AX-B-protein
adducts, thus raising the possibility that cellular proteins could
contribute to the formation of haptens involved in the develop-
ment of adverse reactions towards AX.
Discussion
Drug binding to proteins plays a key role in the development of
drug allergy. Here we have prepared and characterized a
biotinylated derivative of AX (AX-B) and evaluated its ability to
modify serum and/or cellular proteins, as indicated by 1D and
2D-electrophoresis analysis, as well as its recognition by anti-AX
antibodies, to explore its potential as a tool for the study of protein
haptenation. Our results show the usefulness of AX-B in the
detection of adducts with serum proteins with high sensitivity, as
well as in the detection of intracellular adducts. These properties
can be exploited to obtain novel information on the mechanisms of
the allergic reactions towards AX.
Biotinylated derivatives of reactive drugs or endogenous
compounds have been widely used as tools to identify the targets
of the parent compounds [19,33,34]. These approaches take
advantage of the high affinity of the avidin-biotin interaction,
characterized by an affinity constant of 1015 M-1, which in general
appears to be three to six orders of magnitude higher than for the
interaction of ligands with their specific antibodies [35], this
property likely underlying the superior sensitivity of these methods.
Here we have observed that both AX and AX-B display similar
reactivity towards simple amines. Moreover, both compounds
compete for their binding to proteins, suggesting that they may
bind to common sites. In addition, we have observed that both
compounds bind to the same serum targets, with the only
difference of a weak binding to haptoglobin, which is undetectable
using immunological AX detection, but is visible with AX-B due to
the higher sensitivity of this method. Thus, both compounds seem
to display similar binding to proteins. Nevertheless, it should be
taken into account that the presence of the biotin moiety may
impose steric impediments for binding to some targets or it may
shield part of the molecule [36]. Indeed, AX-B adducts are not
recognized by a monoclonal antibody directed towards the lateral
chain of the AX molecule, which in AX-B is modified by the
attachment of the biotin moiety. Also, results from RAST
inhibition assays indicate that recognition of AX-B by the sera
of non-selective patients is similar to that of AX, but it is poorer in
the case of patients with allergy selective towards AX, whose IgE
recognize AX lateral chain. Therefore, a detailed characterization
of the binding of AX to the individual targets identified through
the use of AX-B would be necessary. An interesting aspect of the
RAST inhibition studies as well as of other in vitro tests using ‘‘free’’
b-lactams is that, during incubation, adducts of the b-lactams
assayed and the proteins present in the assay, either from serum or
from cells, will be formed (Ariza et al., unpublished observations).
Therefore, these structures may also contribute to the selectivity
observed and should be taken into account in the interpretation of
the results.
Several strategies have been used to detect and identify targets
and sites of action of b-lactam antibiotics, including various MS
approaches recently developed, allowing a detailed characteriza-
tion of HSA haptenation by various b-lactams [12,37,38].
Immunological approaches have also been used in various
Figure 8. Detection of intracellular AX-B-protein adducts. (A)
Raw264.7 murine macrophages were incubated in the absence or
presence of AX for 24 h, after which, formation of AX-protein adducts
was assessed by SDS-PAGE of cell lysates and detection with AO3.2
antibody. The position of two of the bands detected above background
is marked by arrowheads. (B) Cells were incubated with the indicated
concentrations of AX-B and protein adducts present in cell extracts
were detected by SDS-PAGE, transfer and detection with HRP-
streptavidin. The position of endogenous biotinylated proteins is
marked by arrows and that of the major labeled proteins is indicated by
asterisks. (C) Cells were incubated with biotin and the presence of
biotinylated proteins was assessed as in (B). (D) Cells were incubated
with the indicated concentrations of AX for 24 h, after which, AX-B was
added at 0.3 mg/ml and incubation was continued for an additional
24 h. Incorporation of AX-B into proteins was assessed as above.
doi:10.1371/journal.pone.0090891.g008
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experimental systems. In particular, a selective modification of
certain cytokines after in vitro incubation with high concentrations
of BP, even in the presence of serum, has been evidenced by
western blot [39]. In a recent work using also immunological
detection, the only piperacillin adducted protein detected in the
cell culture medium of T-lymphocytes incubated with this
antibiotic was albumin. Moreover, no cellular adducts were
detected [40]. Nevertheless, our results indicate that highly
sensitive methods can allow the detection and identification of
novel AX targets in serum and in cell culture, either in cells or in
the extracellular medium. In fact, when the supernatant from cells
cultured in the presence of AX-B was analyzed by blot and
detection with streptavidin, a whole array of adducts was observed
(results not shown). Moreover, we have clearly observed the
presence of intracellular protein adducts by confocal fluorescence
microscopy. Intracellularly detected protein adducts could corre-
spond to extracellular proteins internalized by cells, either from
the culture medium or from the plasma membrane, or to
intracellular proteins. Interestingly, the covalent binding of AX
to HLA class I molecules present at the membrane of B cells
overexpressing these molecules has been reported [41]. However,
under our conditions, the plasma membrane of AX-B-treated
macrophages showed negligible biotin labeling. Interestingly, our
results also indicate that AX-B may form different adducts in
distinct cell types. Therefore, it would be interesting to assess
whether binding of AX-B to membrane proteins can be observed
in other cell types or under different culture conditions. On the
other hand, the presence of intracellular targets for covalent
Figure 9. Localization and cell-type specificity of AX-B adducts. (A) RAW264.7 macrophages were cultured in the absence or presence of
0.5 mg/ml AX-B in serum-free medium for 24 h, after which, cells were fixed with paraformaldehyde and biotin positive structures were visualized by
staining with Alexa-488-streptavidin. Nuclei were stained with DAPI. Shown is a single z section at mid cell height. DIC, differential interference
contrast. Bar, 20 mM. (B) RAW264.7 cells (left panel), monocytic THP-1 (middle panel) and B lymphoma cells (right panel) were incubated with AX-B
and the presence of AX-B-protein adducts was analyzed by SDS-PAGE and biotin detection with HRP-streptavidin and ECL. Typically, aliquots from
total protein extracts containing 15 mg of protein were analyzed. Endogenous biotinylated polypeptides are marked by arrows and the position of
the polypeptides showing higher biotin incorporation after AX-B treatment is indicated by asterisks.
doi:10.1371/journal.pone.0090891.g009
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modification by AX may increase the panoply of potential
antigenic determinants generated by treatment with the antibiotic.
AX is known to enter mammalian cells and several transporters
have been described that mediate the entry of b-lactam antibiotics,
especially in kidney and liver cells [42,43]. In addition, intracel-
lular AX has been detected by immunocytochemistry, using an
anti-AX antibody, in nuclei and cytoplasm of absorptive epithelial
cells of the intestine and in hepatocytes [10]. Therefore, the nature
of intracellular AX adducts and their potential role in allergy
towards AX deserves future investigation.
From various studies, the concept of the selectivity of protein
modification by AX and other b-lactams is beginning to emerge.
The results herein presented also point towards a selective
modification since some abundant serum proteins appear not to
be modified by either AX or AX-B. Modification of HSA in vitro
and in vivo by b-lactams shows selectivity, with some residues being
preferentially modified. Moreover, in cell extracts, only some
polypeptides show AX-B incorporation. Residue reactivity and
conformational factors which favor b-lactam docking may play an
important role in this selectivity [12,40]. Identification and
characterization of additional targets will help define the structural
factors favoring AX addition.
In summary, our results show that use of highly sensitive
approaches such as labeling with biotinylated analogs will allow
the detection of novel targets of AX. Detailed structural
information on the binding sites on various targets will provide
potential new antigenic determinants to be used in diagnostic
procedures and in studies on the mechanisms of AX-induced
allergy.
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